Apimeds Pharmaceuticals Reports Merger with MindWave Innovations and Increased Losses in Fiscal Year 2025

Apimeds Pharmaceuticals US, Inc. reported significant developments in its fiscal year 2025, highlighted by a merger with MindWave Innovations Inc. on December 1, 2025. This merger transformed Apimeds into a dual-segment operating company, adding a digital asset operations segment alongside its biopharmaceutical business. The merger resulted in the acquisition of approximately $145.3 million in identifiable net assets, primarily digital assets, and was executed through the issuance of 7,477,017 shares of Series A Convertible Preferred Stock. The company has not yet generated revenue from its biopharmaceutical operations, focusing instead on advancing its clinical development of Apitox, a honeybee venom-based drug candidate aimed at treating knee osteoarthritis.

Financially, Apimeds reported a net loss of $6.0 million for the year ended December 31, 2025, compared to a net loss of $1.4 million in the previous year. The increase in losses was attributed to expanded operational activities related to the IPO and the merger, alongside increased research and development expenses of $1.6 million, which were non-existent in the prior year. General and administrative expenses surged to $10.2 million from $1.3 million, driven by the costs associated with becoming a public company and the merger, including consulting fees, payroll, and stock-based compensation.

The company’s operational metrics indicate a strategic focus on clinical development, with a significant increase in research activities related to Apitox. Apimeds has established a prepaid balance of approximately $2 million with its Clinical Research Organization to support future clinical trial execution. The company also reported total operating expenses of $11.9 million for the year, reflecting the scale-up of operations and development activities.

Looking ahead, Apimeds faces challenges regarding liquidity and capital resources, with cash and cash equivalents totaling $1.6 million as of December 31, 2025. The company plans to address its liquidity needs through additional tranches under a Securities Purchase Agreement, which allows for the issuance of up to $129 million in senior secured convertible notes. However, there is no assurance that future financing will be available on acceptable terms. The company’s ability to continue as a going concern is contingent upon successfully advancing its clinical development and securing additional capital.

In summary, Apimeds Pharmaceuticals US, Inc. is navigating a transformative phase marked by a merger that has diversified its operations while incurring significant losses as it invests in the development of its biopharmaceutical pipeline. The company is focused on advancing Apitox through clinical trials, with an eye on future revenue generation, while also managing the complexities of its new digital asset operations segment.